Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)

Background/Aims: Baseline factors and early decline in serum hepatitis C virus RNA are predictive of sustained virological response to interferon therapy in patients with chronic hepatitis C. We evaluated the prognostic value of baseline factors and early viral RNA among patients treated with pegint...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of hepatology 2002-10, Vol.37 (4), p.500-506
Hauptverfasser: Lee, Samuel S, Heathcote, E.Jenny, Reddy, K.Rajender, Zeuzem, Stefan, Fried, Michael W, Wright, Teresa L, Pockros, Paul J, Häussinger, Dieter, Smith, Coleman I, Lin, Amy, Pappas, Stephen C
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background/Aims: Baseline factors and early decline in serum hepatitis C virus RNA are predictive of sustained virological response to interferon therapy in patients with chronic hepatitis C. We evaluated the prognostic value of baseline factors and early viral RNA among patients treated with peginterferon alfa-2a (40KD). Methods: Data were pooled from three randomized trials involving 814 patients treated with peginterferon alfa-2a (40KD) (90, 135, or 180 μg). Stepwise and multiple logistic regression identified independent baseline factors associated with response. Receiver operating characteristic curves for both absolute values and log 10 decline in viral RNA at 4, 8, 12 and 24 weeks of therapy were created. Results: Independent prognostic factors for sustained virological response included viral genotype non-1, low pretreatment viral load, age (10) were also independently prognostic. Receiver operating characteristic curves showed that detectable or less than 2-log 10 decline in viral RNA at week 12 predicted sustained virological non-response (negative predictive value is 98%). Conclusions: In patients with chronic hepatitis C treated with peginterferon alfa-2a (40KD), the decision to continue or stop treatment can be made as early as week 12.
ISSN:0168-8278
1600-0641
DOI:10.1016/S0168-8278(02)00211-8